Late Urinary Toxicity and QoL with Curative Radiotherapy for High -Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase Ill Trial

被引：0
|
作者：
Maheshwari, G. [1 ]
Maitre, P. [1 ]
Sarkar, J. [1 ]
Raveendran, V. [2 ]
Phurailatpam, R. [1 ]
Singh, P. [1 ]
Murthy, V. [1 ]
机构：
[1] Homi Bhabha Natl Inst, Dept Radiat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India
[2] Homi Bhabha Natl Inst, Dept Med Phys, Tata Mem Ctr, Mumbai, Maharashtra, India
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
284
引用
收藏
页码：S94 / S95
页数：2
相关论文
共 50 条
  • [31] Stereotactic body radiotherapy for high-risk prostate cancer (5 treatment days): Toxicity results of a phase II trial.
    Kishan, Amar Upadhyaya
    Fuller, Donald B.
    Steinberg, Michael L.
    Ramirez, Victoria
    Agazaryan, Nzhde
    Ruan, Dan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [32] Comparison of urinary toxicity between patient reported outcomes and physician evaluation in high risk prostate cancer treated with radiotherapy and hormonal therapy: data from a phase II trial
    Nabid, Abdenour
    Carrier, Nathalie
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Vavassis, Peter
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Duclos, Marie
    Souhami, Luis
    [J]. QUALITY OF LIFE RESEARCH, 2019, 28 : S132 - S133
  • [33] Single-dose radiotherapy (SDRT) in the management of intermediate risk prostate cancer: Early results from a phase II randomized trial.
    Greco, Carlo
    Pimentel, Nuno
    Pares, Oriol
    Louro, Vasco
    Fuks, Zvi Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [34] 1056 PRELIMINARY RESULTS OF LATE RECTAL AND URINARY TOXICITY IN A PHASE II RANDOMIZED STUDY OF CONVENTIONAL FRACTIONATION VS. HYPOFRACTIONATION ON PATIENTS WITH HIGH RISK PROSTATE CANCER.
    Petrongari, M. G.
    Gomellini, S.
    Saracino, B. M.
    Arcangeli, S.
    Marzi, S.
    Landoni, V.
    Strigari, L.
    Arcangeli, G.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S337 - S337
  • [35] Phase I Dose-Escalation Trial of Stereotactic Ablative Body Radiotherapy (SAbR) for Men with High-Risk Prostate Cancer
    Salamekh, S.
    Desai, N. B.
    Folkert, M. R.
    Garant, A.
    Mannala, S.
    Mohamad, O.
    Choy, H.
    Roehrborn, C.
    Lotan, Y.
    Timmerman, R. D.
    Hannan, R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E869 - E869
  • [36] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
    Rosenthal, Seth A.
    Hu, Chen
    Sartor, Oliver
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark G.
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George B.
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott G.
    Hannan, Raquibul
    Horwitz, Eric M.
    Raben, Adam
    Peters, Christopher A.
    Feng, Felix Y.
    Shipley, William U.
    Sandler, Howard M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1159 - +
  • [37] Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes
    Loblaw, Andrew
    Musunuru, Bindu
    Cheung, Patrick
    Vesprini, Danny
    Liu, Stanley K.
    Chu, William
    Chung, Hans T.
    Morton, Gerard
    Deabreu, Andrea
    Davidson, Melanie
    Ravi, Ananth
    Helou, Joelle
    Ho, Ling
    Zhang, Liying
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients
    Darius Norkus
    Agata Karklelyte
    Benedikt Engels
    Harijati Versmessen
    Romas Griskevicius
    Mark De Ridder
    Guy Storme
    Eduardas Aleknavicius
    Ernestas Janulionis
    Konstantinas Povilas Valuckas
    [J]. Radiation Oncology, 8
  • [39] A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients
    Norkus, Darius
    Karklelyte, Agata
    Engels, Benedikt
    Versmessen, Harijati
    Griskevicius, Romas
    De Ridder, Mark
    Storme, Guy
    Aleknavicius, Eduardas
    Janulionis, Ernestas
    Valuckas, Konstantinas Povilas
    [J]. RADIATION ONCOLOGY, 2013, 8
  • [40] Acute Toxicity Following Single-Dose Radiation Therapy in the Management of Intermediate Risk Prostate Cancer: Results from a Phase 2 Randomized Trial
    Greco, C.
    Pares, O.
    Pimentel, N.
    Louro, V.
    Arcangeli, S.
    Pinzi, V.
    Possanzini, M.
    Nunes, B.
    Morales, J.
    Stroom, J.
    Viera, S.
    Fuks, Z.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E236 - E236
12345